Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia

Matti Tikkanen, Jari Ojala, Eero Helve
Published 1991 in European Journal of Clinical Pharmacology

Abstract

Subanalyses of previous multicenter studies comparing lovastatin and gemfibrozil were carried out to evaluate the merits of these agents in patients with different serum lipid phenotypes (type 2a and 2b hyperlipoproteinemia). Regardless of phenotype, lovastatin was more effective in lowering LDL-cholesterol, while gemfibrozil had a greater triglyceride… (More)

DOI: 10.1007/BF01409403

References

Showing 1-7 of 7 references

Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study.

J P Ojala, E Helve, M J Tikkanen
Cardiology
1990

Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group.

M J Tikkanen, T S Bocanegra, J F Walker, T Cook
The American journal of medicine
1989

J Tikkanen M, E Helve, +7 authors J Viikari
Am J Cardio162:35 J~3 J
1988

Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.

P Schulzeck, M Bojanovski, A Jochim, H Canzler, D Bojanovski
Lancet
1988

E Helve, MJ Ojala J-R Tikkanen
J Appl Cardiol
1988

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

M H Frick, O Elo, +7 authors V Manninen
The New England journal of medicine
1987

Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis.

H N Ginsberg, N A Le, M P Short, R Ramakrishnan, R J Desnick
The Journal of clinical investigation
1987

Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia

Abstract

Topics

4 Figures and Tables

Cited By

References

Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study.

Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group.

Afirynen M, and the Finnish Lovastatin Study Group (1988) Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The Finnish Multicenter Study

Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.

Simvastatin and gemfi- brozil in the treatment of primary hypercholesterolemia

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis.

Slides referencing similar topics

Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia

Abstract

Topics

4 Figures and Tables

Cited By

References

Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study.

Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group.

Afirynen M, and the Finnish Lovastatin Study Group (1988) Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The Finnish Multicenter Study

Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.

Simvastatin and gemfi- brozil in the treatment of primary hypercholesterolemia

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis.

Similar Papers

Slides referencing similar topics